Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (412)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2093)
  2. Meeting Abstract (2072)
  3. Book Section (179)
  4. Review (88)
  5. Editorial (80)
  6. Guidelines (35)
  7. Correspondence (24)
  8. Book Whole (17)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (65)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1666)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
    Meeting Abstract

    Raoof, S.; Tafazzoli, A.; Kansal, A.; Shaul, A.; Ye, W.; Fendrick, M.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
    Meeting Abstract

    Reuss, J.; Leung, C. H.; Rosner, S.; Zhou, N.; Weissferdt, A.; Pataer, A.; Nassib William, W. Jr; Taube, J.; Broderick, S.; Spicer, J. D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
    Meeting Abstract

    Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
    Meeting Abstract

    Guardamagna, M.; Marqueste, C. G.; Malissen, N.; Roy, S.; da Silva, I. P.; Long, G. V.; Smithy, J. W.; Postow, M. A.; Dimitriou, F.; Dummer, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
    Meeting Abstract

    Lebbe, C.; Nghiem, P.; Bhatia, S.; Mortier, L.; Brohl, A. S.; Jacob, N.; Tyroller, K.; Hoffman, J.; D'Angelo, S. P.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
    Meeting Abstract

    Cohen, J. V.; Garyantes, T. K.; Muller, C.; Natale, C. A.; Orloff, M.; Patel, S.; Rodon, J.; Shoushtari, A. N.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
    Meeting Abstract

    Klempner, S. J.; Shen, L.; Liu, D.; Dayyani, F.; Kratz, J.; Pan, H.; Liang, X.; Wang, Z.; Kim, S.; Deng, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
    Meeting Abstract

    Burton, E.; Wani, K.; Milton, D.; Lazcano, R.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Patel, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, V. T.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save